Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 9/20 | 0.43 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | PLK1 | P53350 | 4/20 | 0.41 |
| ▸ | PLK3 | Q9H4B4 | 4/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL979549 | 0.89 | S1PR1 (0.39) | SPHK1 | |
| SCHEMBL979832 | 0.84 | LMNA (0.45) | ALDH1A1L3MBTL1 | |
| SCHEMBL979605 | 0.83 | SPHK1 (0.50) | SPHK1SPHK2PLK1PLK3 | |
| SCHEMBL34475170 | 0.80 | TMEM97 (0.48) | ALDH1A1L3MBTL1 | |
| SCHEMBL15775037 | 0.78 | TMEM97 (0.41) | CNR2ALDH1A1 | |
| SCHEMBL981221 | 0.75 | SPHK1 (0.51) | SPHK1SPHK2PLK1PLK3 | |
| SCHEMBL977493 | 0.75 | S1PR1 (0.44) | SPHK1 | |
| SCHEMBL12923356 | 0.73 | SPHK1 (0.54) | SPHK1SPHK2PLK1PLK3ALDH1A1 | |
| Iodide SCHEMBL982259 | 0.73 | SPHK1 (0.49) | SPHK1SPHK2PLK1PLK3 | |
| SCHEMBL978529 | 0.73 | SMN1; SMN2 (0.47) | ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680282-B2 | Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2014-03-25 | — | — | US | disclosed |
| US-20110015174-A1 | CYCLIC INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2011-01-20 | — | — | US | disclosed |
| WO-2009015485-A1 | CYCLIC INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015174-A1 | CYCLIC INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | CPT1A, CPT1B, CPT2 | SPHK1 186/4885SPHK2 310/4885HDAC1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.